| Identification | Back Directory | [Name]
BMS-688521 | [CAS]
893397-44-9 | [Synonyms]
BMS-688521
BMS688521,BMS 688521
LILGMDXLRPEBNH-HFZDXXHNSA-N
6-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4,4]non-7-yl]-3-pyridinecarboxylic acid | [Molecular Formula]
C26H19Cl2N5O4 | [MOL File]
893397-44-9.mol | [Molecular Weight]
536.37 |
| Chemical Properties | Back Directory | [Boiling point ]
780.4±70.0 °C(Predicted) | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
2.87±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model[1]. | [in vivo]
BMS-688521 (1-10 mg/kg; p.o.; BID for a three-day) is efficacious in a mouse allergic eosinophilic lung inflammation model[1].
BMS-688521 (5 mg/kg; p.o.) treatment shows the Cmax, Tmax, AUC, F values are 0.32 μM, 1.0 μM, 1.5 μM h, and 50%, respectively[1].
BMS-688521 (1 mg/kg; i.v.) treatment shows the T1/2, MRT, CL and Vss values are 1.6 hours, 1.7 hours, 50 mL/mim/kg, and 5.1 L/kg, respectively in BALB/c mice[1]. | Animal Model: | BALB/c female mice, 6-8 week of age (OVA Lung Inflammation in Mice)[1] | | Dosage: | 1, 3, and 10 mg/kg | | Administration: | p.o.; BID for a three-day | | Result: | Significant inhibition of eosinophil accumulation was seen at a dose of 1 mg/kg BID, with dose-dependent inhibition at 3 mg/kg and 10 mg/kg. |
| [storage]
Store at -20°C | [References]
[1] Watterson SH, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4 DOI:10.1021/jm100348u |
|
|